Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788

Completed · Phase 1 · Has a placebo group

Conditions studied: Safety in Normal Volunteers

In brief

The primary objective of the study is to determine the safety of single doses of orally administered EDP-788. Secondary objectives of the study are: * To describe the pharmacokinetics of EDP-788 (and its metabolite EDP-322) after single doses of orally administered drug * To estimate the bioavailability of EDP-788 capsules relative to an oral liquid suspension * To estimate the effect of co-administration of food on the absorption of EDP-788

Key facts

Study ID

NCT01999725

Run by

Enanta Pharmaceuticals, Inc

People needed

80

Starts

2014-01-01

Expected to finish

2014-09-01

Last updated by the study team

2015-01-09

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

Where it is running

• PPD Phase I Clinic — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.